Aspire-Lakewood Holdings, Inc.

Snapshot

Aspire Biopharma is a tiny, cash-strapped biotech that is attempting a dramatic pivot into the automotive industry. The core biopharma business is effectively dormant, generating only $6K in revenue in FY 2025 while burning through $24.5M in net losses. The company has survived by issuing massive amounts of new shares, diluting existing holders by 116% in a single year, and executing two extreme reverse stock splits (1-for-40 and 1-for-30) to avoid delisting.

What's Happening Right Now

• Fri 12th Jun '26 · Acquisition: Aspire signed a definitive agreement to buy Dura Driver Control Systems, a major automotive supplier with $200M+ in revenue, for $30M in cash.
• Thu 28th May '26 · Shareholder Letter: CEO Kraig Higginson issued a letter to shareholders describing 2026 as a defining year for the company's strategic transformation.
• Thu 7th May '26 · Reverse Split: Aspire executed a 1-for-30 reverse stock split in May 2026, following a 1-for-40 split in January, to maintain Nasdaq listing compliance.
• Mon 27th Apr '26 · Buyback: The board authorized a $5M share repurchase program, signaling confidence in its balance sheet despite recent financial distress.
• Mon 20th Apr '26 · Financing: The company closed the final tranche of a $21M private placement and secured a $22.5M credit facility to fund the acquisition.